[go: up one dir, main page]

WO2006037960A3 - Recepteurs de lymphocytes t a liaison intercatenaire disulfure exogene reliee a des agents therapeutiques - Google Patents

Recepteurs de lymphocytes t a liaison intercatenaire disulfure exogene reliee a des agents therapeutiques Download PDF

Info

Publication number
WO2006037960A3
WO2006037960A3 PCT/GB2005/003752 GB2005003752W WO2006037960A3 WO 2006037960 A3 WO2006037960 A3 WO 2006037960A3 GB 2005003752 W GB2005003752 W GB 2005003752W WO 2006037960 A3 WO2006037960 A3 WO 2006037960A3
Authority
WO
WIPO (PCT)
Prior art keywords
tcr
cell receptors
terminus
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2005/003752
Other languages
English (en)
Other versions
WO2006037960A2 (fr
Inventor
Bent Karsten Jakobsen
Torben Bent Andersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avidex Ltd
Original Assignee
Avidex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0421836.8A external-priority patent/GB0421836D0/en
Priority claimed from GB0427584A external-priority patent/GB0427584D0/en
Application filed by Avidex Ltd filed Critical Avidex Ltd
Priority to MX2007003910A priority Critical patent/MX2007003910A/es
Priority to JP2007534081A priority patent/JP2008514685A/ja
Priority to EP05787358A priority patent/EP1809669A2/fr
Priority to AU2005291039A priority patent/AU2005291039A1/en
Priority to CA002582963A priority patent/CA2582963A1/fr
Publication of WO2006037960A2 publication Critical patent/WO2006037960A2/fr
Publication of WO2006037960A3 publication Critical patent/WO2006037960A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)

Abstract

La présente invention, qui concerne des récepteurs de lymphocytes T ou 'TCR' (T-Cell Receptor), concerne plus particulièrement un TCR dimère (dTCR) ou un TCR monocaténaire (scTCR) associé à des agents thérapeutiques sélectionnés. Un premier segment de ce TCR est une séquence d'acides aminés correspondant à une séquence de domaine variable de la chaîne a du TCR, fusionnée à la terminaison N d'une séquence d'acides aminés correspondant à une séquence extracellulaire du domaine constant de la chaîne a du TCR. Un deuxième segment de ce TCR est une séquence d'acides aminés correspondant à un domaine variable de la chaîne ß du TCR fusionnée à la terminaison N d'une séquence d'acides aminés correspondant à une séquence extracellulaire du domaine constant de la chaîne ß du TCR. Les deux chaînes sont reliées par une liaison disulfure qui est d'un type sans équivalent dans les récepteurs des lymphocytes T aß endogènes. Dans le cas des scTCR considérés, on a également une séquence de liens reliant la terminaison C du premier segment à la terminaison N du second segment, ou réciproquement. La longueur de la séquence de liens et la position de la liaison disulfure sont telles que les séquences de domaines variables des deux segments sont mutuellement orientés sensiblement comme dans les récepteurs des lymphocytes T aß endogènes.
PCT/GB2005/003752 2004-10-01 2005-09-29 Recepteurs de lymphocytes t a liaison intercatenaire disulfure exogene reliee a des agents therapeutiques Ceased WO2006037960A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MX2007003910A MX2007003910A (es) 2004-10-01 2005-09-29 Receptores de celulas t que contienen un enlace entre cadenas bisulfuro no nativo ligado a agentes terapeuticos.
JP2007534081A JP2008514685A (ja) 2004-10-01 2005-09-29 治療剤に連結した、非天然型ジスルフィド鎖間結合を含有するｔ細胞レセプター
EP05787358A EP1809669A2 (fr) 2004-10-01 2005-09-29 Recepteurs de lymphocytes t a liaison intercatenaire disulfure exogene reliee a des agents therapeutiques
AU2005291039A AU2005291039A1 (en) 2004-10-01 2005-09-29 T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
CA002582963A CA2582963A1 (fr) 2004-10-01 2005-09-29 Recepteurs de lymphocytes t a liaison intercatenaire disulfure exogene reliee a des agents therapeutiques

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB0421836.8A GB0421836D0 (en) 2004-10-01 2004-10-01 T cell receptors containing a non-native disulfide interchain bond linked to immunomodulatory agents
GB0421836.8 2004-10-01
US62106304P 2004-10-25 2004-10-25
US60/621,063 2004-10-25
GB0427584.8 2004-12-16
GB0427584A GB0427584D0 (en) 2004-12-16 2004-12-16 T cell receptors containing a novel disulfide interchain bond linked to immunomodulatory agents

Publications (2)

Publication Number Publication Date
WO2006037960A2 WO2006037960A2 (fr) 2006-04-13
WO2006037960A3 true WO2006037960A3 (fr) 2006-08-03

Family

ID=36000822

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/003752 Ceased WO2006037960A2 (fr) 2004-10-01 2005-09-29 Recepteurs de lymphocytes t a liaison intercatenaire disulfure exogene reliee a des agents therapeutiques

Country Status (6)

Country Link
EP (1) EP1809669A2 (fr)
JP (1) JP2008514685A (fr)
AU (1) AU2005291039A1 (fr)
CA (1) CA2582963A1 (fr)
MX (1) MX2007003910A (fr)
WO (1) WO2006037960A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103130894A (zh) * 2011-11-30 2013-06-05 中国医学科学院基础医学研究所 抗人γδTCR单克隆抗体的重组单链抗体G5-4ScFv及其编码基因与应用

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1699826T3 (da) 2005-01-05 2009-07-06 Star Biotechnologische Forschung Syntetiske immunoglobulindomæner med bindende egenskaber konstrueret i regioner af molekylet forskellig fra de komplementaritets-bestemmende domæner
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
EP3241842B1 (fr) 2007-06-26 2024-01-31 F-star Therapeutics Limited Présentation d'agents de liaison
EP2113255A1 (fr) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Immunoglobuline cytotoxique
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
CN102161998B (zh) * 2011-01-14 2013-01-09 中国人民解放军军事医学科学院附属医院 基于b7-1-pe40kdel外毒素融合基因的dna疫苗及其用途
JP6100764B2 (ja) 2011-06-09 2017-03-22 アメリカ合衆国 免疫原性の低いｔ細胞及び／又はｂ細胞エピトープを有するシュードモナス外毒素ａ
AU2012308591B2 (en) 2011-09-16 2017-02-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pseudomonas exotoxin a with less immunogenic B cell epitopes
JP2014530009A (ja) * 2011-09-29 2014-11-17 エーピーオー‐ティー ビー．ヴイ． 異常細胞を標的とする多重特異性結合分子
WO2013105856A1 (fr) 2012-01-13 2013-07-18 Apo-T B.V. Immunoglobulines restreintes à une cellule aberrante dotées d'une fraction toxique
EP3015477B1 (fr) 2013-06-26 2021-08-18 XLifeSc, Ltd. Récepteur de lymphocytes t de haute stabilité et son procédé de préparation et son application
JP6415716B2 (ja) * 2014-11-07 2018-10-31 グアンドン シャンスエ ライフ サイエンス， リミテッド． 可溶性のヘテロ二量体ｔ細胞受容体およびその製法と使用
CN106279404A (zh) * 2015-05-20 2017-01-04 广州市香雪制药股份有限公司 一种可溶且稳定的异质二聚tcr
WO2017193107A2 (fr) 2016-05-06 2017-11-09 Juno Therapeutics, Inc. Cellules génétiquement modifiées et leurs procédés de fabrication
MX2018014863A (es) 2016-06-02 2019-09-11 Immunocore Ltd Régimen de dosificación para proteína de fusión de tcr especifico de gp100 - scfv anti - cd3.
CN110291402B (zh) 2016-06-27 2023-09-01 朱诺治疗学股份有限公司 鉴定肽表位的方法、结合此类表位的分子和相关用途
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
MA46354A (fr) 2016-10-03 2019-08-07 Juno Therapeutics Inc Molécules se liant spécifiquement au vph
CA3044682A1 (fr) * 2016-12-02 2018-06-07 University Of Southern California Recepteurs immunitaires synthetiques et leurs procedes d'utilisation
WO2018148445A1 (fr) 2017-02-08 2018-08-16 Adimab, Llc Protéines de fixation multi-spécifiques destinées à l'activation de cellules tueuses naturelles et leurs utilisations thérapeutiques pour traiter le cancer
JP7685821B2 (ja) 2017-02-20 2025-05-30 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質
EP4215543A3 (fr) 2017-10-03 2023-10-11 Juno Therapeutics, Inc. Molécules de liaison spécifiques du vph
SG11202003862PA (en) 2017-11-01 2020-05-28 Editas Medicine Inc Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
CN111556893A (zh) 2017-11-06 2020-08-18 爱迪塔斯医药股份有限公司 免疫疗法t细胞中cblb的crispr-cas9编辑的方法、组合物和组分
US12384847B2 (en) 2018-02-08 2025-08-12 Dragonfly Therapeutics, Inc. Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
WO2019157366A1 (fr) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Domaines variables d'anticorps ciblant le récepteur nkg2d
MX2020008684A (es) 2018-02-20 2020-12-07 Dragonfly Therapeutics Inc Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso.
US20210015869A1 (en) 2018-04-05 2021-01-21 Juno Therapeutics, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
SG11202009284TA (en) 2018-04-05 2020-10-29 Juno Therapeutics Inc T cell receptors and engineered cells expressing same
EP3775238A1 (fr) 2018-04-05 2021-02-17 Juno Therapeutics, Inc. Procédés de production de cellules exprimant un récepteur recombinant et compositions associées
EA202091977A1 (ru) * 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
BR112021002276A2 (pt) 2018-08-08 2021-05-04 Dragonfly Therapeutics, Inc. proteínas de ligação a nkg2d, cd16 e um antígeno associado ao tumor
CA3108427A1 (fr) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Proteines de liaison multi-specifiques se liant a bcma, nkg2d et cd16, et methodes d'utilisation
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
MX2021001523A (es) 2018-08-09 2021-05-27 Juno Therapeutics Inc Procesos para generar células modificadas y composiciones de las mismas.
SG11202102108QA (en) 2018-09-11 2021-04-29 Juno Therapeutics Inc Methods for mass spectrometry analysis of engineered cell compositions
US12404331B2 (en) 2019-04-19 2025-09-02 Tcrcure Biopharma Corp. Anti-PD-1 antibodies and uses thereof
AU2020265741A1 (en) 2019-05-01 2021-11-25 Editas Medicine, Inc. Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
CA3172447A1 (fr) 2020-03-27 2021-09-30 Erik Hans MANTING Utilisation in vivo de cellules modifiees d'origine leucemique pour ameliorer l'efficacite d'une therapie cellulaire adoptive
AU2021243864A1 (en) 2020-03-27 2022-11-03 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
WO2021260186A1 (fr) 2020-06-26 2021-12-30 Juno Therapeutics Gmbh Lymphocytes t modifiés exprimant un récepteur recombiné, polynucléotides et procédés associés
US12364758B2 (en) 2020-06-30 2025-07-22 Mendus B.V. Use of leukemia-derived cells in ovarian cancer vaccines
WO2022060904A1 (fr) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions et procédés pour l'expression de récepteurs de lymphocytes t avec cd40l régulé par petites molécules dans les lymphocytes t
WO2022097068A1 (fr) 2020-11-05 2022-05-12 Dcprime B.V. Utilisation d'antigènes indépendants de tumeurs dans des immunothérapies
CN116723854A (zh) 2021-01-22 2023-09-08 门德斯有限公司 肿瘤疫苗接种方法
CN117222663A (zh) 2021-03-03 2023-12-12 蜻蜓疗法股份有限公司 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
AU2022269828A1 (en) 2021-05-05 2023-11-23 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
WO2023081900A1 (fr) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Lymphocytes t modifiés exprimant un récepteur recombiné de lymphocytes t (tcr) et systèmes et procédés apparentés
CN116496408A (zh) * 2022-01-21 2023-07-28 广东菲鹏制药股份有限公司 白细胞介素21及其受体复合物
WO2023196884A1 (fr) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Dosage pour la détection du papillomavirus humain (vph) de type 16 (hpv-16)
US20240002800A1 (en) 2022-05-16 2024-01-04 Mendus B.V. Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020763A2 (fr) * 2001-08-31 2003-03-13 Avidex Limited Substances
WO2004033685A1 (fr) * 2002-10-09 2004-04-22 Avidex Ltd Recepteurs de lymphocytes t de recombinaison a chaine unique
WO2004044004A2 (fr) * 2002-11-09 2004-05-27 Avidex Limited Presentation de recepteurs pour l'antigene des lymphocytes t
WO2004050705A2 (fr) * 2002-12-03 2004-06-17 Avidex Ltd. Recepteurs
WO2004074322A1 (fr) * 2003-02-22 2004-09-02 Avidex Ltd Recepteur des lymphocytes t soluble modifie

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020763A2 (fr) * 2001-08-31 2003-03-13 Avidex Limited Substances
WO2004033685A1 (fr) * 2002-10-09 2004-04-22 Avidex Ltd Recepteurs de lymphocytes t de recombinaison a chaine unique
WO2004044004A2 (fr) * 2002-11-09 2004-05-27 Avidex Limited Presentation de recepteurs pour l'antigene des lymphocytes t
WO2004050705A2 (fr) * 2002-12-03 2004-06-17 Avidex Ltd. Recepteurs
WO2004074322A1 (fr) * 2003-02-22 2004-09-02 Avidex Ltd Recepteur des lymphocytes t soluble modifie

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOULTER JONATHAN M ET AL: "Stable, soluble T-cell receptor molecules for crystallization and therapeutics.", PROTEIN ENGINEERING. SEP 2003, vol. 16, no. 9, September 2003 (2003-09-01), pages 707 - 711, XP002379684, ISSN: 0269-2139 *
REITER Y ET AL: "CONSTRUCTION OF A FUNCTIONAL DISULFIDE-STABILIZED TCR FV INDICATES THAT ANTIBODY AND TCR FV FRAMEWORKS ARE VERY SIMILAR IN STRUCTURE", IMMUNITY, CELL PRESS, US, vol. 2, no. 3, March 1995 (1995-03-01), pages 281 - 287, XP009004075, ISSN: 1074-7613 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103130894A (zh) * 2011-11-30 2013-06-05 中国医学科学院基础医学研究所 抗人γδTCR单克隆抗体的重组单链抗体G5-4ScFv及其编码基因与应用
CN103130894B (zh) * 2011-11-30 2017-04-12 中国医学科学院基础医学研究所 抗人γδTCR单克隆抗体的重组单链抗体G5‑4ScFv及其编码基因与应用

Also Published As

Publication number Publication date
MX2007003910A (es) 2007-06-07
JP2008514685A (ja) 2008-05-08
CA2582963A1 (fr) 2006-04-13
EP1809669A2 (fr) 2007-07-25
AU2005291039A1 (en) 2006-04-13
WO2006037960A2 (fr) 2006-04-13

Similar Documents

Publication Publication Date Title
WO2006037960A3 (fr) Recepteurs de lymphocytes t a liaison intercatenaire disulfure exogene reliee a des agents therapeutiques
NO20052198L (no) Enkeltkjedede, rekombinante T-cellereseptorer
JP2006502741A5 (fr)
HRP20220865T1 (hr) T stanični receptori
WO2014052451A3 (fr) Dimères analogues de l'insuline
UY31123A1 (es) Proteinas de fusion natriureticas
HRP20170086T1 (hr) Bifunkcionalni polipeptidi
DE60319745D1 (de) Modifizierter löslicher t-zellen-rezeptor
IN2015DN02913A (fr)
PE20120514A1 (es) Fusiones y conjugados de agentes insulinotropicos o farmacos incretina con anticuerpos dab anti-albumina serica
DK2231860T3 (da) Polypeptid afledt protein A og i stand til at binde PDGF
CY1121580T1 (el) ΝΕΟΙ ΠΡΟΑΓΩΓΕΙΣ β-ΑΚΤΙΝΗΣ ΚΑΙ RPS21 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
WO2004094613A3 (fr) Complexe proteinique polyvalent
PL1761553T3 (pl) Peptydy charakterystyczne dla nowotworów, wiążące się z cząsteczkami MHC
MX382756B (es) Polimeros de tiol-eno degradables y metodos para hacer los mismos.
JP2008535826A5 (fr)
BRPI0920573A8 (pt) Complexos tcr imunoterapêuticos
SG10201807877TA (en) Hybrid immunoglobulin containing non-peptidyl linkage
NZ737844A (en) Vista regulatory t cell mediator protein, vista binding agents and use thereof
PL1873166T3 (pl) Ulepszone dimery sgp 130Fc
WO2007062037A3 (fr) Compositions et methodes de production de molecules hybrides de fixant a des antigenes, et leurs utilisations
MX2009002999A (es) Analogos de insulina resistentes a proteasa.
PE20171325A1 (es) Polipeptidos del receptor de activina variante y uso de los mismos
PE20140260A1 (es) Compuestos antidiabeticos
WO2006001023A3 (fr) Proteines chimeres et utilisations associees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/003910

Country of ref document: MX

Ref document number: 2007534081

Country of ref document: JP

Ref document number: 2582963

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005291039

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 554616

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005787358

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005291039

Country of ref document: AU

Date of ref document: 20050929

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200580039381.3

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005787358

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2005787358

Country of ref document: EP